BillionToOne plans to launch an expanded Unity Fetal Risk Screen NIPT offering plus a tissue-of-origin add-on for its Northstar Select liquid biopsy assay. The company tied the roadmap to rising quarterly performance, reporting Q2 revenue up 64%. The additions aim to expand risk stratification and interpretive guidance for therapy selection, aligning with the broader push to bundle NIPT and liquid biopsy outputs into decision-support workflows used by clinicians and payors.